TORONTO, ON / ACCESSWIRE / June 18, 2015 / Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the Biotechnology Industry Organization (“BIO“) Conference on Thursday, June 18, 2015 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 10:30 am ET.

About BIO Exhibition:

The world’s largest biotechnology gathering, the BIO exhibition allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies.

The 2015 BIO exhibition will feature more than 1,700 exhibitors and approximately 160,000 square feet. The exhibition also includes 60+ state, regional and country pavilions who in turn host many companies from their regions.

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase(R)“) (TSXV: TLT) (TLTFF:OTC Pink) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO, Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 429924

41% Average Increase in all Five Endpoints Evaluated

SAN DIEGO, CA / ACCESSWIRE / June 18, 2015 / Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCQB: INNV)
a company focusing on the commercialization of over-the-counter (“OTC”)
and consumer products for men’s and women’s health, vitality and
respiratory diseases, announced today that the Company’s top line
results from its Vesele(R) U.S. human
survey clinical use trial in women with low female sexual dysfunction
accompanying endpoints including: 1/ desire; 2/ Lubrication; 3/frequency
of sexual intercourse; and 4/ ability to be aroused. Endpoints assessed
in this study were designed to assess Hypoactive Sexual Desire Disorder
(“HSDD”).

In the study, the Company reported that Vesele(R) use resulted in the following:

1. 58% increase desire;
2. 40% increase in lubrication;
3. 34.2% increase in the frequency of sexual intercourse;
4. 45.9% increase in the ability to be aroused; and
5. 41% increase in overall satisfaction.

About the VES-002 Use Survey Trial.

– Method: Scores were assessed at initiation of trial, midpoint and conclusion. A five‐
point satisfaction scale was used. Satisfaction was summarized by
combining scores from the users’ Mostly Satisfied, Satisfied, and Very
Satisfied responses. Dissatisfaction was summarized using results from
Dissatisfied and Very Dissatisfied responses.
– Subjects: 40 patients completed the study in the United States.
– Age: Over 50% of participants who
completed the trial were between the ages of 40‐59. Over 70% who
completed the study were age 40 and older. This was true at the baseline
of the study as well.
– Regimen: two capsules twice a day for a total of 16 weeks.

Pursuant to these results, the Company believes that the data indicate that Vesele(R) was very well tolerated with no serious adverse events reported. The
only minor events reported by the clinical trial patients were dry
mouth, which was resolved by their drinking 62oz of water daily and
sleep disturbance if taken late afternoon.

Vesele(R) is a proprietary oral formulation of arginine and citrulline with the natural absorption enhancer Bioperine(R). Vesele(R) was formulated to increase blood flow and nitric oxide production.

“We are thrilled about these results from the Vesele(R) study and the magnitude of the responses achieved by the users” said Dr. Bassam Damaj, President & Chief Executive Officer of Innovus Pharma. “To our knowledge, there are no approved products in the U.S. for HSDD.
The closest product, we believe, is in late stage development by Sprout
Pharmaceuticals and it is awaiting FDA approval. Hence, we believe the
market is open for Vesele(R) to be successful in the U.S. for this indication,” continued Dr. Damaj.

About Vesele(R)

Vesele(R) is a proprietary, novel
oral dietary supplement to maximize nitric oxide’s beneficial effects on
sexual function and brain health. Vesele(R) contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine(R).

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma
is an emerging leader in OTC and consumer products for men’s and
women’s health and vitality. The Company generates revenues from its
lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare(TM) OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myadroferti.com

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, receiving
approval or to be compliant with the requirements of any relevant
regulatory authority, to successfully commercialize Vesele(R) and other products and to achieve its other development,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from
the SEC’s website or without charge from the Company.

Contact:

Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410.825-3930

SOURCE: Innovus Pharmaceuticals, Inc.

ReleaseID: 429931

NEW BRUNSWICK, NJ / ACCESSWIRE / June 18, 2015 / The free “Auto Insurance Saver” tool from DavidOsler.com is rapidly growing in popularity nationwide as more of the driving public finds they are often paying much more than necessary for car insurance. The free “Auto Insurance Saver” tool from DavidOsler.com is a unique automated auto insurance rate quote shopping tool available in most every state in the United States. Go here to use the free auto insurance rate saver tool now http://www.davidosler.com/.

The service is completely free and can be used by drivers without obligation throughout the United States. Many insurance industry professionals say many Americans are typically overpaying for car insurance by $350 to $600 annually, sometimes much more. The state with the highest auto insurance rates is currently Michigan for the second year running. Among the states with the lowest rates are North Carolina
and Maine.

The regional statistics currently indicate the Detroit/Warren/Ann Arbor, Michigan areas have the highest rates, seen here: http://www.davidosler.com/auto-insurance-quotes/michigan-auto-insurance/,
followed by the New York, NY and Newark NJ metro area.

Shopping for car insurance the old way is time-consuming, frustrating and confusing. That’s why so many people often just pay their bill and try not to think much about this expensive necessity. But many auto insurance policies are overpriced or contain
unnecessary coverage. That’s where the free, consumer-friendly automated “Auto
Insurance Saver’ rate quote tool from DavidOsler.com comes in. This popular free tool makes auto insurance rate quote comparison-shopping simple and very effective. The motto at DavidOsler.com is that when insurance professionals compete for a drivers business, rate shopping becomes easy and savings come fast.

It is often recommended
by insurance experts to reevaluate auto insurance policies annually to reexamine current rates and find out if there are better deals available from other insurers. That’s because auto policy offerings change frequently along with the insured’s specific personal situation like change of zip code, age of vehicle, type of vehicle and more.

And, it’s best for
consumers to initiate the research rather expecting a call from one’s current insurance
company, which may never come. The popular “Auto Insurance Saver” tool from
DavidOsler.com makes such research fast and effective.

Click here to use the free “Auto Insurance Saver” tool http://www.davidosler.com/.

About
DavidOsler.com

DavidOsler.com
operates the free automated auto insurance rate-shopping tool called “Auto Insurance Saver” currently available in most every state in the United States. The unique tool enables consumers to quickly access competing auto insurance rate quotes from a number of select top insurance providers who are competing for the driver’s insurance business, without being required to enter too much personal information. DavidOsler.com is a leading online auto insurance shopping marketplace that connects consumers with select insurance company agents. DavidOsler.com does not provide quotes directly to consumers. DavidOsler.com does not provide insurance and is not a licensed insurance provider but connects consumers with select insurance agents via its unique, free “Auto Insurance Saver” tool.

SOURCE: DavidOsler.com

ReleaseID: 429929